 |
|
| DRUG DISCOVERY TODAY
| |
| | |
|
|
 (incorporating Pharmaceutical Science and Technology Today)
Editor
Steve Carney
See editorial board for all editors information
Visit the Drug Discovery Today website
Description
Drug Discovery Today delivers informed and highly current reviews for the discovery community. The
magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial
and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.
Features include comment
by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent
progress in specific therapeutic areas and conference reports.
Coverage includes:
• Novel therapeutic strategies
•
High-throughput screening
• Therapeutic targets
• Combinatorial chemistry, parallel synthesis and library design
•
Drug delivery
• ADME/Tox
• Advances in key compound classes and therapeutic areas
• Genomics and proteomics
• Automation and technology
• Virtual chemistry
• Informatics
• Business strategy
• Clinical
trials
and other aspects of drug discovery.
Ethics in Publishing: General Statement
The Editor(s) and Publisher
of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount
to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors'
own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in
a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted
to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance
are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject
privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately
to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will
employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors
to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist
when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately
influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions
to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The
Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important
to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.
For
more information, please refer to:  http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest
| Bibliographic details |
ISSN: 1359-6446
Imprint: TRENDS
Subscriptions for the year 2009,
Volume 14,
24 issues |
| Price and Ordering |
Personal price:
JPY 37,800 for Japan
EUR 317 for European countries and Iran
USD 345 for all countries except Europe, Japan and Iran
|  |
Institutional price:
USD 3,204 for all countries except Europe, Japan and Iran
JPY 398,500 for Japan
EUR 2,863 for European countries and Iran
| |
Conditions of sale & ordering procedures, and links to our regional sales offices.
|
For an overview of recently-dispatched issues, see the Journal issue
dispatch dates
Audience
Scientists, managers and other professionals in the pharmaceutical and biotechnology sectors, and academic centres focusing on related
research. These will include organic, bioorganic and bioinorganic chemists, biochemists, pharmacologists and pharmaceutical scientists,
molecular biologists and geneticists, microbiologists, medicinal chemists, and biotechnologists.
Impact factor of this journal
2007: 6.761
© Journal Citation Reports 2008, published by Thomson Reuters
602/188
Last update: 7 Oct 2008
|
|
| |
| | |
|
|
| |
